Hyrimoz

Adalimumab, the active ingredient in Hyrimoz, is a TNF-alpha inhibitor presented as an injection solution for subcutaneous use. It treats autoimmune inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa in adult patients.

GNH USA supplies Hyrimoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is distributed under strict quality controls.

Adalimumab is a TNF-alpha inhibitor used to manage several chronic inflammatory and autoimmune diseases. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: alleviates joint pain and skin lesions. - Ankylosing spondylitis: improves spinal mobility and reduces pain. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve clinical remission and mucosal healing. - Plaque psoriasis: decreases plaque formation and skin scaling. - Hidradenitis suppurativa: reduces lesion count and disease severity.

Adalimumab therapy may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: redness, swelling, or pain. - Upper respiratory infections: nasopharyngitis or sinusitis. - Headache: mild to moderate. - Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects: - Serious infections: tuberculosis, bacterial sepsis, or opportunistic fungal infections. - Malignancies: increased risk of lymphoma or skin cancers. - Hepatic injury: elevated liver enzymes or hepatitis. - Demyelinating disorders: new or worsening multiple sclerosis‑like symptoms.

When prescribing Adalimumab, clinicians should consider several safety precautions to minimize risks. - Screening for latent TB: perform tuberculin skin test or interferon‑γ release assay before initiation. - Monitor for infections: advise patients to report signs of serious infection promptly. - Assess hepatitis status: test for hepatitis B and C and manage accordingly. - Evaluate heart failure: avoid use in patients with moderate to severe congestive heart failure. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with obstetrician. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection; avoid administering live vaccines. - Antifungal agents (e.g., azoles): may increase risk of opportunistic infections when combined. - Immunosuppressants (e.g., azathioprine, methotrexate) at high doses: may heighten infection risk.

Moderate Interactions (Monitor Closely): - Cytokine‑targeted therapies (e.g., other biologics): increased immunosuppression risk. - NSAIDs: may exacerbate gastrointestinal ulcer risk. - Concomitant steroids: monitor for additive infection risk.